Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 626

Sort by

Sort Order Select

Journal Articles

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

Kaushik Das, Shiva Keshava, Shabbir A. Ansari, Vijay Kondreddy, Charles T. Esmon, John H. Griffin, Usha R. Pendurthi, L. Vijaya Mohan Rao

Blood (2021) 137 (24): 3428–3442.

https://doi.org/10.1182/blood.2020008417

Published: 2021

Includes: Supplemental data

Journal Articles

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Jhansi Magisetty, Usha R. Pendurthi, Charles T. Esmon, L. Vijaya Mohan Rao

Blood (2020) 135 (25): 2211–2223.

https://doi.org/10.1182/blood.2019003824

Published: 2020

Includes: Supplemental data

Journal Articles

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Paulette Bryant, MD, Jenny McDaniel, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 1126.

https://doi.org/10.1182/blood-2019-126659

Published: 2019

Journal Articles

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Carolyne Elbaz, MD, Katerina Pavenski, MD, Hina Chaudhry, BSc, Jerome M. Teitel, MD FRCPC, Michelle Sholzberg, MDBSc,FRCPC,MSc

Blood (2019) 134 (Supplement_1): 1128.

https://doi.org/10.1182/blood-2019-122260

Published: 2019

Journal Articles

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 904.

https://doi.org/10.1182/blood-2019-132050

Published: 2019

Journal Articles

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Loula Papageorgiou, Despina Fotiou, BMBS, MA, Patrick Van Dreden, PhD, Laurent Garderet, MD PhD, Meletios A. Dimopoulos, MD, Ismail Elalamy, MD PhD, Mohamad Mohty, MD PhD, Grigoris Gerotziafas, MD PhD

Blood (2019) 134 (Supplement_1): 1913.

https://doi.org/10.1182/blood-2019-126954

Published: 2019

Journal Articles

Off-Label Utilization Trend for Recombinant Factor VIIa in Children's Hospitals in the United States

Shveta Gupta, MBBS, Joseph R. Stanek, MS, Sarah H. O'Brien, MD

Blood (2019) 134 (Supplement_1): 2177.

https://doi.org/10.1182/blood-2019-126294

Published: 2019

Journal Articles

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Marianne Kjalke, PhD, Mads Kjelgaard-Hansen, Søren Andersen, Ida Hilden

Blood (2019) 134 (Supplement_1): 3639.

https://doi.org/10.1182/blood-2019-122301

Published: 2019

Journal Articles

Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy

Blood (2019) 134 (Supplement_1): 3642.

https://doi.org/10.1182/blood-2019-129901

Published: 2019

Journal Articles

Patients with Familial Thrombophilia of Unknown Origin Show Low APC Response to In Vivo Thrombin Formation in Stimulated Hemostasis Activity Pattern Evaluation (SHAPE)

Heiko Rühl, MD, Sara Reda, MD, Franziska Isabelle Winterhagen, Christina Berens, MD, Jens Müller, Johannes Oldenburg, Bernd Pötzsch, MD

Blood (2019) 134 (Supplement_1): 3647.

https://doi.org/10.1182/blood-2019-124507

Published: 2019

Journal Articles

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Ammon Fager, MD PhD, Maureane Hoffman, MD PhD, Dougald Monroe, PhD

Blood (2019) 134 (Supplement_1): 3623.

https://doi.org/10.1182/blood-2019-124428

Published: 2019

Journal Articles

The Endothelial Protein C Receptor (EPCR) Regulates Endogenous Factor VII Levels in Mice

Juliana Small, PhD, Shannon Zintner, PhD, Lynn E Dankner, Paris Margaritis, DPhil

Blood (2019) 134 (Supplement_1): 3629.

https://doi.org/10.1182/blood-2019-130596

Published: 2019

Journal Articles

Disease Burden in Patients with Glanzmann Thrombasthenia: Perspectives from the Glanzmann Thrombasthenia Patient/Caregiver Questionnaire

Alexander Duncan, MD, Angela Kellum, PharmD, Shilpa Jain, Skye Peltier, Helen Smith, David Cooper, Hossam Saad

Blood (2019) 134 (Supplement_1): 3456.

https://doi.org/10.1182/blood-2019-128408

Published: 2019

Journal Articles

Monitoring of Recombinant Activated Coagulation Factor VII (rFVIIa) Therapy in Patients (pts) with Inherited Factor VII (FVII) Deficiency

Gennadii M. Galstian, Olesya A. Polevodova, MD, Elena Yakovleva, MD PhD, Antonina Shchekina, MD, Igor Davydkin, MD PhD, Dmitriy Kudlay, MD PhD

Blood (2019) 134 (Supplement_1): 2412.

https://doi.org/10.1182/blood-2019-124709

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC)

Sara Reda, MD, Franziska Isabelle Winterhagen, Christina Berens, MD, Jens Müller, Johannes Oldenburg, Bernd Pötzsch, MD, Heiko Rühl, MD

Blood (2019) 134 (Supplement_1): 2389.

https://doi.org/10.1182/blood-2019-124731

Published: 2019

Journal Articles

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Xin Ying Lee, Katarina Cepo, Thomas Porstmann

Blood (2019) 134 (Supplement_1): 2419.

https://doi.org/10.1182/blood-2019-122827

Published: 2019

Journal Articles

A Lipid Peroxidation Product, 4-Hydroxy-2-Nonenal, Triggers Intravascular Coagulation and Inflammation through Generation of Tissue Factor-Positive Microvesicles

Shabbir Ansari, PhD, Shiva Keshava Gaddam Bala Krishna, PhD, Usha R. Pendurthi, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 2383.

https://doi.org/10.1182/blood-2019-124498

Published: 2019

Journal Articles

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Laurent Burnier, PhD, Mette B Hermit, PhD, Ida Hilden, Mirella Ezban, PhD, Stine L Kjellev, PhDDVM

Blood (2019) 134 (Supplement_1): 2388.

https://doi.org/10.1182/blood-2019-123340

Published: 2019

Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 2420.

https://doi.org/10.1182/blood-2019-128971

Published: 2019

NARROW

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Hypercoagulability Biomarkers in a New Score Linked to Treatment Resistance for Multiple Myeloma Patients. the Roadmap-MM Study

Off-Label Utilization Trend for Recombinant Factor VIIa in Children's Hospitals in the United States

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy

Patients with Familial Thrombophilia of Unknown Origin Show Low APC Response to In Vivo Thrombin Formation in Stimulated Hemostasis Activity Pattern Evaluation (SHAPE)

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

The Endothelial Protein C Receptor (EPCR) Regulates Endogenous Factor VII Levels in Mice

Disease Burden in Patients with Glanzmann Thrombasthenia: Perspectives from the Glanzmann Thrombasthenia Patient/Caregiver Questionnaire

Monitoring of Recombinant Activated Coagulation Factor VII (rFVIIa) Therapy in Patients (pts) with Inherited Factor VII (FVII) Deficiency

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Circulating Plasminogen Activator Inhibitor-1 (PAI-1) Is Reduced By In Vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC)

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

A Lipid Peroxidation Product, 4-Hydroxy-2-Nonenal, Triggers Intravascular Coagulation and Inflammation through Generation of Tissue Factor-Positive Microvesicles

Evaluation of a Next-Generation FVIII Mimetic Antibody, Mim8, in Combination with Recombinant FVIIa, FVIII and Activated Prothrombin Complex Concentrate

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only